Gradientech is a Swedish diagnostics company dedicated to supporting the modern microbiology lab with state-of-the-art solutions that facilitate the testing of time-critical sepsis samples.

Gradientech is currently developing the in vitro diagnostic QuickMIC^® system, a new platform for ultra-rapid testing of antibiotic resistance. The system is expected to become the most rapid solution for determining the appropriate antibiotic treatment of sepsis patients. Rapid testing of antibiotic resistance is vital for increasing sepsis patient survival, reducing healthcare costs, and lowering the spread of antibiotic resistance.

Antibiotic resistance is a global call and the World Health Organization has stressed the urgent need for new rapid diagnostic solutions that can guide proper antibiotic treatment and reduce antibiotic misuse. Gradientech aspires to meet this need by setting a new standard of care where it will no longer be acceptable to wait for days to obtain urgent and critical results.

Sepsis and antibiotic resistance – Global challenges in need of solutions

Sepsis affects 50 million people every year of which about 20% do not survive – every 3 seconds someone dies of sepsis. Time is critical: Sepsis survival rates decrease dramatically with every hour of inappropriate antibiotic treatment. Sepsis is also becoming harder to treat as antibiotics are losing their effectiveness due to the rising antibiotic resistance levels.

Early sepsis detection and adequate treatment administration positively impact the human and economic burden of sepsis. Prescribing the right antibiotic, at the right dose and at the right time is critical for the successful management of the patient. To achieve optimal therapy, the patient’s clinical condition and diagnostic test results need to be checked frequently to reassess antibiotic therapy and tailor the treatment as needed.

Our solution: Faster testing saves lives

QuickMIC is our novel state-of-the-art diagnostic solution that outperforms current solutions by providing results that can guide sepsis treatment in 2-4 hours, instead of days.

• Save lives: Actionable results in record-time mean that sepsis patients can receive appropriate, targeted antibiotic treatment faster than ever before.
• Cut hospital costs: Earlier, appropriate sepsis treatment leads to shorter hospital stays, which reduces hospital expenditure.
• Combat antibiotic resistance: Personalized treatment of sepsis patients reduces unnecessary antibiotic use and reduces the spread of antibiotic resistance.